In adults with HIV maintaining viral suppression, switching from dolutegravir plus lamivudine (DTG/3TC) to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) does not improve inflammatory or metabolic outcomes over 96 weeks,…
The 24-hour news cycle is just as important to medicine as it is to politics, finance, or…







